| Company Name: |
Shanghai Chaolan Chemical Technology Center
|
| Tel: |
021-QQ：65489617 15618227136 |
| Email: |
Sales@ATKchemical.com |
| Products Intro: |
Product Name:TJ-M2010-5
CAS:1357471-57-8
Purity:98% Package:5MG;10MG;50MG;100MG,1G,5G,100G
|
| Company Name: |
MQ (shanghai) Pharmaceuticals Co., Ltd.
|
| Tel: |
13761635123 |
| Email: |
1014988033@qq.com |
| Products Intro: |
Product Name:3-(4-Benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl)propanamide
CAS:1357471-57-8
Purity:＞95% Package:1G，5G
|
| Company Name: |
Shanghai Dongyang Biotechnology Co., Ltd.
|
| Tel: |
0512-0512-13601744364 13601744364 |
| Email: |
chemsharker@126.com |
| Products Intro: |
Product Name:TJ-M2010-5
CAS:1357471-57-8
Purity:98% Package:1g 5g 10g 25g 50g 100g
|
|
| | TJ-M2010-5 Basic information |
| Product Name: | TJ-M2010-5 | | Synonyms: | TJ-M2010-5;ischemia,MIRI,Anoxia,factor,MyD88,injury,reoxygenation,inhibit,reperfusion,differentiation,Inhibitor,remodeling,myocardial,MyD88,TLR,TJ-M-2010-5,myeloid,TJM20105,TJ M2010 5;3-(4-Benzylpiperazin-1-yl)-N-(4-phenylthiazol-2-yl)propanamide;1-Piperazinepropanamide, 4-(phenylmethyl)-N-(4-phenyl-2-thiazolyl)- | | CAS: | 1357471-57-8 | | MF: | C23H26N4OS | | MW: | 406.54 | | EINECS: | | | Product Categories: | | | Mol File: | 1357471-57-8.mol |  |
| | TJ-M2010-5 Chemical Properties |
| density | 1.232±0.06 g/cm3(Predicted) | | solubility | DMSO : 100 mg/mL (245.98 mM; Need ultrasonic) | | pka | 9.36±0.50(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | TJ-M2010-5 Usage And Synthesis |
| Biological Activity | TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway[1][2]. TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI)[2].
TJ-M2010-5 (40 μM) inhibits MyD88 homodimerization in transfected HEK293 cells in a concentration-dependent manner and suppresses MyD88 signaling in LPS (100 ng/mL)-responsive RAW 264.7 cells in vitro[1].TJ-M2010-5 (5-30 μM) prevents B cell proliferation and induces B cells apoptosis after stimulation with R848 (500 ng/mL)[3].
TJ-M2010-5 treatment statistically significantly reduces AOM/DSS-induced colitis and completely prevented CAC development with less related body mass loss, results in 0% mortality of treated mice, decreases cell proliferation, and increased apoptosis in colon tissue in a 10-week CAC mouse model[1].TJ-M2010-5 statistically significantly decreases TNF-α, IL-6, G-CSF, MIP-1β, IL-11, IL-17A, IL-22, and IL-23 serum concentrations in mice at both two and seven weeks postinduction, as well as TGF-β1 serum levels at seven weeks postinduction[1]. | | References | [1]. Lin Xie, et al. Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer. J Natl Cancer Inst. 2015 Dec 28;108(4):djv364. [2]. Yan Miao,et al. Inhibition of MyD88 by a novel inhibitor reverses two-thirds of the infarct area in myocardial ischemia and reperfusion injury.Am J Transl Res. 2020 Sep 15;12(9):5151-5169. |
| | TJ-M2010-5 Preparation Products And Raw materials |
|